Author | Jessica Skarzynski


Carfilzomib Triplet Fails to Induce Superior PFS in Newly Diagnosed Multiple Myeloma

May 29, 2020

Carfilzomib combined with lenalidomide and dexamethasone failed to improve progression-free survival, compared with the current standard of care triplet of bortezomib, lenalidomide, and dexamethasone, in patients with newly diagnosed multiple myeloma.